Group 1 - The article discusses the recent performance of Mesa Laboratories, Inc. (MLAB), highlighting a recovery in its share price from the $70s to nearly $100 in recent weeks, indicating a potential investment opportunity in the life science tools sector [1] - The service "Value in Corporate Events" provides coverage of major corporate events such as earnings reports, M&A, and IPOs, aiming to identify actionable investment ideas [1] - The investing group focuses on finding the best opportunities by analyzing around 10 major events each month, which includes tracking companies through catalytic events [1]

Search fieldEntering text into the input field will update the search result belowEntering text into the input field will update the search result below ...

LAKEWOOD, Colo., March 09, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that Gary Owens will step down as President and CEO on April 12, 2026, and will enable a smooth leadership transition. “Gary has served as Mesa’s CEO since 2017, leading Mesa through a period of significant growth, expansion into new markets, the maturation of the comp ...

Core Insights - Conestoga Capital Advisors reported that US equities had solid returns in 2025, with double-digit gains across major indices, but underlying conditions showed extreme volatility and market leadership [1] - The Small Cap Strategy of Conestoga Capital Advisors returned -1.89% net-of-fees in Q4 2025, underperforming the Russell 2000 Growth Index, which returned 1.22% [1] - The rally in "low quality" stocks continued in Q4 2025, albeit at a slower pace compared to previous quarters [1] Company-Specific Insights - Mesa Laboratories, Inc. (NASDAQ:MLAB) is a provider of life sciences tools and quality control products, with a one-month return of 11.32% but a 52-week loss of 35.06% [2] - As of February 19, 2026, Mesa Laboratories, Inc. had a stock price of $92.02 and a market capitalization of $508.393 million [2] - Conestoga Capital Advisors expressed concerns about Mesa Laboratories' long-term growth prospects, citing pressures from end-market weakness, particularly in cell and gene therapy and in China [3] - The company exited its position in Mesa Laboratories due to insufficient conviction in its growth potential and limited organic growth opportunities [3] - Mesa Laboratories was not among the 30 most popular stocks among hedge funds, with 20 hedge fund portfolios holding the stock at the end of Q3 2025, an increase from 12 in the previous quarter [5] - Conestoga Capital Advisors believes that certain AI stocks present greater upside potential and less downside risk compared to Mesa Laboratories [5]

Revenue Growth - For the nine months ended December 31, 2025, revenues grew by 3.7% to $185,406,000 compared to $178,843,000 in the prior year[92]. - The Biopharmaceutical Development division saw a revenue increase of 10.2% for the nine months ended December 31, 2025, reaching $39,779,000 compared to $36,112,000 in the prior year[96]. - Revenues for the Sterilization and Disinfection Control division increased by 6.0% to $24,914,000 for the three months ended December 31, 2025, and by 5.5% to $72,431,000 for the nine months ended December 31, 2025[100]. - Revenues for the Biopharmaceutical Development division increased by 17.5% to $14,373,000 for the three months ended December 31, 2025, and by 10.2% to $39,779,000 for the nine months ended December 31, 2025[104]. - Revenues for the Calibration Solutions division decreased by 2.5% to $14,072,000 for the three months ended December 31, 2025, but increased by 3.9% to $39,992,000 for the nine months ended December 31, 2025[109]. - Revenues for the Clinical Genomics division declined by 7.1% to $11,767,000 for the three months ended December 31, 2025, and by 6.7% to $33,204,000 for the nine months ended December 31, 2025[113]. Profitability - The gross profit for the nine months ended December 31, 2025, was $116,065,000, representing a 3.2% increase from $112,458,000 in the prior year[97]. - Operating income increased by 6.0% to $15,763,000 for the nine months ended December 31, 2025, compared to $14,867,000 in the prior year[97]. - The net income for the nine months ended December 31, 2025, was $10,848,000, a significant increase of 111.1% from $5,140,000 in the prior year[97]. - The gross profit as a percentage of revenues for the nine months ended December 31, 2025, was 62.6%, slightly down from 62.9% in the prior year[96]. - The company reported a gross profit percentage of 69.5% for the Sterilization and Disinfection Control division for the nine months ended December 31, 2025[96]. - Gross profit for the Biopharmaceutical Development division was $8,920,000, or 62.1% of revenues for the three months ended December 31, 2025, and $23,355,000, or 58.7% of revenues for the nine months ended December 31, 2025[104]. - Gross profit for the Calibration Solutions division was $8,450,000, representing 60.0% of revenues for the three months ended December 31, 2025, and $23,727,000, or 59.3% of revenues for the nine months ended December 31, 2025[109]. - Gross profit for the Clinical Genomics division increased by 5.6 percentage points to 60.5% of revenues for the three months ended December 31, 2025, and by 1.7 percentage points to 56.1% for the nine months ended December 31, 2025[114]. Operating Expenses - Operating expenses increased by 2.8% to $100,302,000 for the nine months ended December 31, 2025, compared to $97,591,000 in the prior year[94]. - Operating expenses increased by 2.8% for the nine months ended December 31, 2025, while remaining flat for the three months ended December 31, 2025[116]. - Selling expenses decreased by 4.4% to $9,986,000 for the three months ended December 31, 2025, but increased by 1.0% to $30,715,000 for the nine months ended December 31, 2025[118]. Cash Flow and Working Capital - Net cash provided by operating activities was $28.9 million for the nine months ended December 31, 2025, a decrease of $5.3 million compared to the prior year[142]. - Working capital improved to $51.2 million as of December 31, 2025, compared to negative working capital of $(61.3) million as of March 31, 2025[134]. - Cash on hand as of December 31, 2025, was $29.0 million, up from $27.3 million as of March 31, 2025[132]. - The company expects to incur approximately $10.2 million in cash interest expense over the next twelve months based on outstanding debt levels[135]. Tax and Non-Operating Expenses - The effective tax rate for the three months ended December 31, 2025, was 21.0%, a decrease of 3.4 percentage points from 24.4% in the prior year[128]. - Total non-operating expense, net, decreased by 57.7% to $3.4 million for the three months ended December 31, 2025, down from $8.0 million in the prior year[124]. - Interest expense for the three months ended December 31, 2025, increased to $3.0 million, a rise of 6.8% compared to $2.8 million in the prior year[124]. Dividends and Shareholder Returns - The company has paid regular quarterly dividends of $0.16 per share since 2003, with the next dividend payable on March 16, 2026[137][138]. Impairment and Currency Gains - The estimated fair value of the Clinical Genomics reporting unit exceeded its carrying value by approximately 40% as of the most recent annual impairment test[140]. - The company recognized unrealized foreign currency gains of approximately $5.8 million during the nine months ended December 31, 2025[125]. Organic Revenue Growth - Total company organic revenue growth for the three months ended December 31, 2025, was 3.6%, compared to 17.5% in 2024[149]. - The Sterilization and Disinfection Control segment reported organic revenue growth of 6.0% for the three months ended December 31, 2025, down from 21.6% in 2024[149]. - Biopharmaceutical Development segment achieved organic revenue growth of 17.5% for the three months ended December 31, 2025, compared to 29.8% in 2024[149]. - Calibration Solutions segment experienced a decline in organic revenue growth of (2.5%) for the three months ended December 31, 2025, down from 18.7% in 2024[149]. - Clinical Genomics segment reported an organic revenue decline of (7.1%) for the three months ended December 31, 2025, compared to a growth of 1.0% in 2024[149]. - For the nine months ended December 31, 2025, total company organic revenue growth was 3.7%, compared to 13.7% in 2024[149]. - The Sterilization and Disinfection Control segment reported organic revenue growth of 5.5% for the nine months ended December 31, 2025, down from 31.2% in 2024[149]. - Biopharmaceutical Development segment achieved organic revenue growth of 10.2% for the nine months ended December 31, 2025, compared to 26.6% in 2024[149]. - Calibration Solutions segment reported organic revenue growth of 3.9% for the nine months ended December 31, 2025, down from 10.1% in 2024[149]. - Clinical Genomics segment experienced a decline in organic revenue growth of (6.7%) for the nine months ended December 31, 2025, compared to (14.2%) in 2024[149].

Revenue Performance - Total revenues for 3Q26 were $65,126, an increase of 3.6% compared to 3Q25 and 7.2% sequentially versus 2Q26[7] - Organic revenue growth was 3.6%, with core organic revenue growth at 1.2%, and 5.7% when excluding Clinical Genomics (CG) China revenues[8] - Biopharmaceutical Development (BPD) revenues increased by 17.5%, driven by higher sales of Immunoassays and Peptides instruments[11] - Clinical Genomics (CG) revenues declined by 7.1%, with a significant contraction in China revenues of approximately $1.2 million, or 57% year-over-year[12] - Sterilization and Disinfection Control (SDC) revenues were $24,914, resulting in organic revenue growth of 6.0%[9] - Calibration Solutions (CS) revenues decreased by 2.5% year-over-year but increased by 3.7% sequentially[10] Income and Profitability - Operating income increased by 38.0% to $7,975, with net income rising 317.0% to $3,630, or $0.65 per diluted share[7] - Adjusted operating income (AOI) was 26.2% as a percentage of revenues, up from 23.5% in 3Q25[5] - GAAP operating income for Q3 2025 was $7,975,000, compared to $5,779,000 in Q3 2024, representing a year-over-year increase of 38.2%[24] - Non-GAAP adjusted operating income (AOI) for Q3 2025 was $17,072,000, up from $14,515,000 in Q3 2024, reflecting a growth of 17.7%[24] - AOI per share (basic) for Q3 2025 was $3.09, compared to $2.67 in Q3 2024, marking a 15.7% increase[24] - AOI excluding unusual items for Q3 2025 was $17,072,000, compared to $14,788,000 in Q3 2024, indicating a growth of 15.5%[24] Debt and Financial Position - The company repaid $8.7 million of debt, reducing the Total Net Leverage Ratio to 2.62[5] Future Outlook - The company expects continued positive momentum in 4Q26, driven by strong execution and stabilization in end markets[6] Currency Impact - Currency translation negatively impacted revenue growth by (2.4)% for Q3 2025 and (1.9)% for the nine months[25] Share Information - The weighted average common shares outstanding for Q3 2025 were 5,532,000 (basic) and 5,565,000 (diluted)[24] Depreciation Expense - The company reported a depreciation expense of $1,270,000 for Q3 2025, compared to $1,106,000 in Q3 2024[24] Unusual Items - Total impact of unusual items on AOI before tax for the nine months ended December 31, 2025, was $848,000[24]

Group 1 - The article does not provide any specific content related to company or industry analysis [1]

Company Overview - Mesa Labs is a diversified tools company focusing on mission-critical quality controls for regulated markets, particularly in the biopharmaceutical sector [2][4] - The company engages in the drug life cycle from the development phase, providing clinical trial support and ensuring drug integrity throughout bioproduction and into the healthcare system [2][4] Mission and Purpose - The company's purpose is human-centric, emphasizing the protection of vulnerable populations by ensuring that drugs are manufactured correctly and are of the highest quality before reaching patients [3] Market Focus - Mesa Labs targets highly regulated end markets, which provide a natural stickiness to their business model, particularly through consumable and recurring revenue streams [4]

Mesa Laboratories FY Conference Summary Company Overview - **Company Name**: Mesa Laboratories (NasdaqGS:MLAB) - **Industry**: Life Science Tools and Biopharmaceuticals - **Focus**: Mission-critical quality controls for regulated markets, particularly in drug development and biopharmaceutical manufacturing [5][6] Core Business Segments - **Segments**: Operates in four segments with a focus on sterility controls, biopharmaceutical development, genomic platforms, and calibration solutions [7][8] - **Revenue**: Reported approximately $240 million in revenue with a five-year CAGR of around 15% [9][10] - **Profitability**: Maintains a gross margin of approximately 63%, indicating strong profitability for a company of its size [10] Growth and Market Dynamics - **Clinical Trials**: Clinical trial starts are a leading indicator for business health; recent trends show a flatlining but are expected to improve [11][42] - **Organic Growth**: The company has improved its organic growth rate from 1% to around 3.5-4% over recent years [11][12] - **Market Headwinds**: The company has faced challenges such as bioprocess destocking, academic funding issues, and regulatory changes, particularly in China [42][43] Strategic Focus - **Acquisitions**: Recent acquisition of GKE, a company specializing in sterility indicators, aimed at enhancing the product portfolio and increasing recurring revenue [26][27] - **Debt Management**: Post-acquisition debt levels were around 3.8-3.9 times but have since been reduced to below 3, with a target of below 2.5 times in the next 12 months [49][50] - **R&D Strategy**: Focuses on sustaining engineering rather than high-level R&D, allowing for quicker returns on investment [50] Future Outlook - **Market Recovery**: Anticipates a recovery in clinical trial starts and overall market conditions, which could lead to accelerated growth rates [44][45] - **Long-term Growth**: Aiming for mid-single-digit growth rates with potential for double-digit growth as market conditions improve [56][57] - **Valuation**: Currently valued at 50%-60% of other profitable diversified life science tool companies, with expectations for valuation improvement as market conditions stabilize [51][53] Key Takeaways - **Human-Centric Approach**: Emphasizes patient safety and quality in drug manufacturing, which differentiates it from competitors [33][34] - **Operational Excellence**: Utilizes a lean-based operating model known as the "Mesa Way" to improve customer satisfaction and operational efficiency [36][37] - **Customer Intimacy**: Focus on understanding customer needs and developing applications that meet those needs effectively [39][40] Conclusion Mesa Laboratories is positioned for growth in the life science tools sector, with a strong focus on quality control in biopharmaceuticals. The company is navigating current market challenges while preparing for future opportunities through strategic acquisitions and a commitment to operational excellence.

Investor Relations Presentation J.P. Morgan 2026 Healthcare Conference Gary Owens, President and CEO John Sakys, CFO Safe Harbor Statement The information provided in this presentation contains forward-looking statements within the meaning of the federal securities laws. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, including statements relating to: projections of revenues, growth, operating results, profit margins, expenses, earni ...